-
公开(公告)号：US20240408249A1
公开(公告)日：2024-12-12
申请号：US18695724
申请日：2022-09-29
Inventor： Natalie Grinshtein , Julie Metcalf , Ian R. Duffy , William Leslie Turnbull , Anne Marcil , Maria Jaramillo , Traian Sulea , Maria Moreno , Cunle Wu
IPC: A61K51/10 , A61P35/00 , C07D257/02 , C07K16/28
Abstract: Compounds, e.g., radioimmunoconjuguates including a chelating moiety or a metal complex thereof, a linker, and an EGFRVIII targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions. e.g., cancer, using such compounds or pharmaceutical compositions.
-
2.发明公开公开(公告)号：US20240197927A1
公开(公告)日：2024-06-20
申请号：US18541604
申请日：2023-12-15
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Diane-Charlotte Imbs , Elodie Lewkowicz , Alexander McEwan , Thomas Rohban , Sylvie Rolland , Daniel Stevens , John R. Forbes
IPC: A61K51/04 , A61K31/7068 , A61K47/64 , A61P35/00
CPC classification number: A61K51/0482 , A61K31/7068 , A61K47/643 , A61P35/00
Abstract: The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
-
公开(公告)号：US20250001019A1
公开(公告)日：2025-01-02
申请号：US18703995
申请日：2022-11-02
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Eric S. Burak , James O'Leary , John Rhoden
Abstract: Methods of treatment for conditions, e.g., cancer, using a cold IGF-1R-targeting molecule and a radioimmunoconjugate comprising a metal complex of a chelating moiety, a linker, and an IGF-1R targeting moiety.
-
公开(公告)号：US20240350682A1
公开(公告)日：2024-10-24
申请号：US18633413
申请日：2024-04-11
Applicant: FUSION PHARMACEUTICALS INC. , ASTRAZENECA UK LIMITED
Inventor： David Rodriguez Caicedo , William Leslie Turnbull , Saleemulla Mahammad , Dewald van Dyk , Darlene Anne Monlish , Vanessa Marie Muniz-Medina , Nathanael David Sallada , Sao Fong Cheung , Jeong Min Han , Frank Irvine Comer , Asurayya Worrede , Chien-ying Chang
CPC classification number: A61K51/1075 , A61K51/1093 , A61P35/00
Abstract: The present disclosure provides compounds or pharmaceutically acceptable salts thereof, e.g., radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting STEAP2. The present disclosure also provides pharmaceutical compositions of such compounds or pharmaceutically acceptable salts thereof and methods of treatment for conditions, e.g., cancer, using such compounds, pharmaceutically acceptable salts thereof, or pharmaceutical compositions.
-
公开(公告)号：US20240139353A1
公开(公告)日：2024-05-02
申请号：US17769232
申请日：2022-03-23
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Natalie Grinshtein , Yaryna Storozhuk
CPC classification number: A61K51/1096 , A61K51/103 , A61P35/00
Abstract: Methods of treatment for conditions, e.g., cancer, using a cold FGFR3-targeting molecule and a radioimmunoconjugate comprising a chelating moiety or a metal complex thereof, a linker, and an FGFR3 targeting moiety.
-
Patent Agency Ranking
公开(公告)号：US20240139333A1
公开(公告)日：2024-05-02
申请号：US18512575
申请日：2023-11-17
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Matthew Guest , Michael B. Johansen , Stuart J. Mahoney
CPC classification number: A61K47/6887 , A61K47/60 , A61K47/6849
Abstract: The present disclosure relates to 2,6-dichlorophenylester compounds. Also disclosed are methods for using the same for the preparation of certain conjugates.
-
公开(公告)号：US11446401B2
公开(公告)日：2022-09-20
申请号：US16619432
申请日：2019-12-03
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Eric Steven Burak , Julie Metcalf , Natalie Grinshtein , Meiduo Hu , John Fitzmaurice Valliant
IPC: A61P37/04 , A61K51/10 , A61P35/00 , A61K31/502 , A61K31/5377 , A61K45/06 , A61K51/04 , A61K39/395 , C07K16/28 , A61P35/04 , A61K39/00
Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
-
公开(公告)号：US20240285818A1
公开(公告)日：2024-08-29
申请号：US18568234
申请日：2022-06-10
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Eric Steven Burak , Julie Metcalf , John Fitzmaurice Valliant , Meiduo Hu , Natalie Grinshtein
IPC: A61K51/10 , A61K39/395 , A61P35/00
CPC classification number: A61K51/1096 , A61K39/3955 , A61K51/1027 , A61K51/103 , A61P35/00 , A61K2121/00
Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
-
公开(公告)号：US20240207455A1
公开(公告)日：2024-06-27
申请号：US18541618
申请日：2023-12-15
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Stephan Klinz , Diane-Charlotte Imbs , Elodie Lewkowicz , Sylvie Rolland , Thomas Rohban , John R. Forbes
IPC: A61K51/04 , A61K9/00 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61P35/02
CPC classification number: A61K51/0482 , A61K9/0019 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61P35/02 , A61K2121/00
Abstract: The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
-
公开(公告)号：US20240165280A1
公开(公告)日：2024-05-23
申请号：US17777850
申请日：2022-04-22
Applicant: Fusion Pharmaceuticals Inc.
Inventor： Eric S. Burak , John R. Forbes , Ryan W. Simms
CPC classification number: A61K51/0497 , A61P35/00
Abstract: The present disclosure relates to methods of treating a subject having cancer with an 225Ac-radiopharmaceutical, which comprises 225Ac chelated with a compound of Formula I:
wherein the compound binds to neurotensin receptor 1 (NTSR1) and does not cross the blood-brain barrier, and wherein the 225Ac-radiopharmaceutical is administered at a dosage of less than 10 MBq/kg of body weight of the subject or is administered as a unitary dosage of less than 40 MBq to the subject.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.017 seconds)
